BeyondSpring Inc. (NASDAQ:BYSI) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $56.00 for the company and are anticipating that the company will post ($0.79) earnings per share for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 102 out of 265 based on the ratings given to related companies.
BYSI has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of BeyondSpring in a report on Monday, August 21st. Zacks Investment Research downgraded BeyondSpring from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Maxim Group reissued a “buy” rating and issued a $52.00 target price on shares of BeyondSpring in a report on Friday, October 27th.
BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. sell-side analysts predict that BeyondSpring will post -4.41 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring as of its most recent SEC filing. 1.22% of the stock is currently owned by hedge funds and other institutional investors.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.